Your API specialist
ICROM is an API CDMO specialized in development and GMP manufacturing of Active Ingredients; with over 50 years of experience, ICROM is the partner of choice for pharmaceutical outsourcing, able to provide a wide range of tailored services, custom development and custom manufacturing of NCEs, generic APIs, ‘high-tech’ and difficult to make molecules for complex formulations.
Leveraging sophisticated know-how, we build high-tech solutions to create complex molecules.
Everything we do for our Customers is driven by a deep passion and the firm belief that Public Health needs high expertise, high quality products, as well as tailor made, fast and reliable solutions.
Our History
1969
ICROM was established by a French entrepreneur, Jean Epuran, as chemical industry for the manufacturing of Active Ingredients for Synthelabo (subsequently merged with Sanofi)
1996
ICROM was acquired by Protex International, a private and family- owned multinational industrial group headquartered in Paris.
2004
The Moor family founded Proxis Développement group as a spin-off of Protex International. ICROM became part of Proxis group, under the leadership of the third generation of the family (Arnaud Moor).
2014
ICROM acquired 6,000 sqm of land adjacent to the existing facility, effectively doubling its surface.
From then, the Company started an important and fruitful period of investments which led to the construction of three new buildings, the revamping of production workshops, the acquisition, in 2018 of an additional piece of land of 3,500 sqm area and a number of additional expansion programs that are currently ongoing and some yet to come.
Click on the arrow to see our Company growth
2014
ACQUISITION OF A NEW EXPANSION AREA
The existing facility has been expanded through the acquisition of 6,000 sqm new area at the south border. Since then, ICROM has started a considerable capital investment program.
2017
NEW HQ BUILDING AND R&D CENTER
With a surface of 1,000 sqm, the building hosts the Headquarters and a state-of-the-art R&D center.
2018
ACQUISITION OF ANOTHER EXPANSION AREA
Another 3,500 sqm area has been acquired for further expansions at the south border.
2021
NEW WAREHOUSES AND QUALITY UNIT BUILDING
With its 900 sqm surface, the new Warehouse building is equipped with semi-automatic shelves allocating over 1,600 pallets, while being integrated with company’s ERP and BAR code management. It also hosts classified dispensing rooms, with someones dedicated to diagnostic pharmaceutical dyes. The Quality Unit Building hosts the brand new and fully equipped Quality Control Laboratory as well as all Quality Unit Operations & offices. In Jan 2021 another 2,500 sqm area has been acquired on the East border.
2022
CLINICAL SCALE PLANT
Equipped with 6 reactors from 100L to 400 L capacity, 3 of which in Hastelloy SS, 1 filter- dryer, 1 centrifuge and a static oven, the new GMP Clinical Scale production workshop is designed to meet the requirements of small scale APIs for clinical programs and it is designed to perform any type of chemical transformation from -80 to 200 °C.
2025
THE CUBE
A new large scale production building which shall host up to 10 complete production lines shall be built starting from 2023 in order to meet ICROM capacity needs for its commercial APIs. Ancillary systems like a post-combustion burner, a new large Water Treatment Plant and Ecologic Areas will be installed on the surface acquired in 2021, to allow a safe management of the production wastes.
Global Business Operations
ICROM provides its services to the global pharmaceutical market, partnering with customers in more than 40 Countries across the Globe, from Europe to North America (USA), from Japan to China, from Middle East to India and Latin America.
© 2022 ICROM. All rights reserved – Privacy Policy
Powered by Eikon Communication